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Exosomes serve as tumour markers for personalized
diagnostics owing to their important role in cancer
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Exosomes, membrane vesicles of 40100 nm in diameter, are derived from endosomes in various cells. The
bioactive molecules specifically packed into exosomes can be horizontally transferred into recipient cells
changing their biological properties, by which tumour cells continuously modify their surrounding
microenvironment and distant target cells favouring cancer metastasis. It has been suspected for a long time
that exosomes participate in the whole process of tumour metastasis. Although there is much unknown and
many controversies in the role of cancer exosome, the major contribution of tumour-associated exosomes
to different steps of cancer metastasis are demonstrated in this review. Mainly because these exosomes are
easily accessible and capable of representing their parental cells, exosomes draw much attention as a promising
biomarker for tumour screening, diagnosis and prognosis. Currently, researchers have found numerous
biomarkers in exosomes with great potential to be utilized in personalized medicine. In this article, we
summarize the roles of biomarkers, which are validated by clinical samples. Even though many conundrums
remain, such as exosome extraction, large multicentre validation of biomarkers and data interpretation,
exosomes are certain to be used in clinical practice in the near future as the field rapidly expands.
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T
he majority of deaths from cancer are ascribed to
metastasis, making it the most fearful aspect of
cancer. Metastasis consists of a series of successive
and interrelated steps mainly including invasion into
surrounding tissue, intravasation, circulation, adhesion
to and extravasation from capillaries in target organs,
proliferation and establishment of micrometastasis illu-
strated in Fig. 1 (1).
To communicate with the stroma cells in the micro-
environment, not only soluble but also membrane-
associated factors, namely extracellular vesicles (EVs) are
secreted from the tumour cells. EVs consist of exosomes,
up to 100 nm in diameter that originate from the fusion
of multivesicular bodies with the plasma membrane and
microvesicles of 50 nm to 1 mm that directly bud from
the plasma membrane (2,3). It seems that exosomes are
released in both constitutive (4) and controlled manners
(5), regulated by intercellular calcium and Rab GTPases
(68). Because of a specific molecule sorting mechanism
in cells (8), proteins, lipids and RNAs in exosome are
different from their parental cells. Ubiquitination asso-
ciated with Endosomal Sorting Complex Required for
Transport, lipids and tetraspanins are proposed as med-
iators in this sorting mechanism (9). A common set of
content as well as an individual subset of component
associated with specific cell functions representative of
its parental cells are contained in exosome (2). As a
carrier, exosomes participate in different stages of cancer
progression by horizontally transferring bioactive mole-
cules to recipients (4). Their cargoes are well protected
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from proteases and nucleases by their phospholipid bilayer.
According to Cocucci’ hypotheses (10), part of the exosome
can transmit the endothelium to the circulation via trans-
cellular and paracellular routes and enter into a variety of
body fluids such as saliva, urine, blood, ascites, breast
milk and cerebrospinal fluid (11).
In terms of their easy access and rapid response to
stimuli, exosomes have been considered as a platform
for personalized diagnostics. Some markers in exosomes
are associated with tumour stratification (12,13) and
prognosis (14), which are highly likely to be exploited as
biomarkers of personalized diagnostics. Although large
sample size validation is required, many companies have
started to develop commercial diagnostics kits based on
exosomes.
In this review, exosomes participation in key steps of
cancer metastasis is considered. In the latter part, the
feasibility and advantages of exosomes in personalized
Fig. 1. The promotion of exosome to cancer metastasis. Tumour-associated exosomes influence other cells and modulate
microenvironment, involving the key steps in cancer metastasis cascade. 1) In primary site, tumour cells secrete exosomes to induce
EMT and degrade the matrix. The Wnt pathway in cancer cells is activated by exosomes during the migration. 2) As intravasation,
endothelium is disturbed directly by tumour-secreted exosomes and indirectly by macrophages activated by exosomes derived from
tumour cells. 3) Both circulating tumour cells (CTCs) and tumour-activated platelets secrete exosomes affecting the immune cells and
CTCs. 4) Adhesive molecules on endothelial cells are upregulated by exosomes from the adherent tumour cell. 5) Disseminated tumour
cells will proliferate forming a micrometastasis in appropriate niche, which is remoulded by exosomes from primary site.
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diagnostics are summarized, as well as current situation
and future challenges in the development of exosome
diagnostics.
The role of exosomes in carcinogenesis
It has been well known that in tumour development, cells
require a long-term, multistage process of carcinogenesis
to accumulate alterations at the genetic and/or epigenetic
level which ultimately reprogramme a cell to undergo
uncontrolled proliferation and metastasis. The expression
of initial mutations depends not only on the internal
interaction between oncogenes but also on external factors
such as exosome, which could change the patterns of
specific gene expression temporarily (15). As an intercel-
lular communicative vector, exosomes facilitate the tumor-
igenesis by transferring both oncogene and oncogenic
factors. Melo et al. found that exosomes derived from
cells and sera of patients with breast cancer lead normal
epithelial cells to form tumours in a Dicer-dependent
way. Then, exosomes derived from cancer cell further
induce surrounding normal cells to become tumorigenic (16).
Furthermore, Lee et al. showed that oncogenic H-ras
promotes the emission of exosomes containing H-ras
DNA and that exosomes may affect the viability and
proliferation of cancer cells through the histones, nucleo-
somes and chromatin enclosed within them (17). Further-
more, Abd Elmageed et al. revealed exosomes to contain
various oncogenic factors, such as H-ras and K-ras
transcripts, oncogenic miRNAs and ras superfamily of
GTPases, and that prostate cancer cell exosomes cause
neoplastic reprogramming of adipose stem cells in vivo
(18). Their finding implicates the function of prostate
cancer cell-derived exosome in tumour clone expansion.
Based on the critical role in carcinogenesis, exosomes
possess the potential to indicate the presence of cancer as a
biomarker and great efforts has been devoted to the
application of exosome.
Exosomes are involved in tumour metastasis
Invasion
Cancer cells at the margin of a tumour, and far from
tumour blood vessels, are often in a hypoxic condition
and likely to invade into surrounding tissue to obtain
more oxygen and nutrients (19). In the beginning, cancer
cells lose their cellcell adhesion and detach from the
primary tumour, a process called epithelialmesenchymal
transition (EMT), which is generally considered the hallmark
of metastasis. During EMT, the epithelial cells decon-
struct their cell junction, lose their polarity and gain
mesenchymal-cell-like migratory and invasive properties.
Tauro et al. found that, compared with control, the
exosome derived from H-ras transformed MDCK cells
containing proteases, annexins and integrins, which may
induce the EMT of a recipient cell (20). Since intercellular
communication can be mediated by the horizontal trans-
fer of information molecules in exosome, it is tempting
to suspect that exosomes can induce and maintain the
EMT (21,22). Recently, Josson et al. co-cultured prostate
cancer cells with the exosomes derived from prostate
stromal cells overexpressing miR-409 resulting in mor-
phologically and biochemically defined EMT. This is
the first study suggesting that stromal-derived exosomal
miRNA can induce EMT in cancer (23).
Once tumour cells leave the primary site, they may be
trapped by the extracellular matrix (ECM) surround-
ing the tumour, which is composed by collagen, laminin,
fibronectin and elastin (24). Various metalloproteinases
are secreted by cancer cells to degrade the ECM, such
as matrix metalloproteinases, ADAM and ADAMTS,
which have been detected in exosomes by proteomic
analysis. Furthermore, it has been clearly proven that
there is a positive correlation between the quantity of
exosomes, the amount of lytic enzymes and in vitro
invasive capability (25).
Subsequently, tumour cells undergo chemotaxis, which
is recognized as an essential part of metastasis. Cell mig-
ration is a continuous cycle of several interdependent
steps including polarization, elongation, extending the
pseudopod attaching to ECM substrate and, finally,
contracting the cell body and trailing edge (24). Increas-
ing numbers of experiments indicate that exosomes are
associated with tumour cell migration. For instance, Lin
et al. determined that exosomes derived from adipose
mesenchymal stem cells promote the migration of MCF-7,
a breast cancer cell line, and that the Wnt/b-catenin
signalling pathway was stimulated (26). Luga et al. found
that Wnt/PCP (planar cell polarity), which can be
activated by CD81 on fibroblast-secreted exosomes, also
plays an important role in breast cancer cell protrusion
and invasive migration (27). On the other hand, it was
determined that exosomes from prostate cancer cells
could transfer integrins to recipient cells thereby mediating
the adhesion of tumour cells to ECM (28). Noticeably,
although tumour cells migration across 2D substrate de-
pends on adhesion, in the 3D situation, cells move in a
cadherin-independent manner akin to amoeboid migration
(24). Additionally, tumour cells can migrate collectively in
several modes (29). Thus, there is a need to further explore
the role of exosomes on the migration of tumour cells
during metastasis (30).
Intravasation
Intravasation as a limiting step in metastasis refers to the
process whereby locally invasive tumour cells enter
lymphatic or blood vessels. To obtain more nutrients
and/or follow chemokine gradients, tumour cells mig-
rate rapidly towards nearby vessels. In the vicinity of
capillaries, tumour cell may slow down and enter a
stage of inactivity, active intravasation or dormancy.
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Once tumour cells pass through the basement membrane,
they will adhere to the vascular endothelial cells (EC)
moving along the vessel wall (31). At some place, tumour
cells undergo transendothelial migration (TEM) to make
a way to the capillary lumen. Not only the properties of
the tumour cell but also other factors such as macro-
phages and cytokines in microenvironment influence the
intravasation (32).
As a carrier, exosomes plays an important function in
the interaction between tumour cells, EC and macro-
phages. For one thing, tumour-derived exosomes can
promote macrophage secretion of several kinds of pro-
inflammatory cytokines, through the NF-kB pathway.
These pro-inflammatory cytokines, such as IL-6, TNF-a
and CCL2, increase the permeability of the endothelial
barrier in favour of TEM (33). Macrophages can also be
activated by MFG-E8 in exosomes derived from prostate
cancer (34). Moreover, exosomes derived from tumour
cells can trigger EC migration, the hallmark of intrava-
sation. For instance, vascular endothelial growth factor
(VEGF) positive tumour exosomes may promote vascular
endothelial cadherin (VE-cadherin), endocytosis, increase
vascular permeability and induce the EC retraction
and matrix degradation (35) as was similarly observed
by Taverna et al. (36). Besides VEGF, other important
factors such as transforming growth factor beta (TGF-b)
and TNF-a harboured in exosomes derived from various
tumours can also facilitate the transmigration (37).
Additionally, Asangani et al. discovered that miR-21
possesses the potential of inducing cancer cell’s intravasa-
tion through reducing Pdcd4 (38). The increase of miR-21
has been found extensively in exosomes derived from
various types of tumours such as laryngocarcinoma (39),
hepatocellular carcinoma (40) and breast cancer (41).
Zhou et al. characterized that miR105-rich exosomes
derived from metastatic breast cancer cell decrease the
tight junction protein ZO-1 with an impairment of the
endothelium integrity (42).
Circulation
Upon intravasation into vessel, the circulating tumour
cell (CTC) has to face many threats like shear force and
immune attack.
One of the principal strategies to combat these is the
absorption of platelets onto cancer cells via the interaction
between P-selectin and its ligand mucin. The formed
emboli prevent the shear force as a physical shield.
Meanwhile, the cancer cell activates adherent platelets
(43) and secretes a great deal of EVs including micro-
vesicles (50 nm to 1 mm) and exosomes (40*to 100 nm).
Janowska-Wieczorek et al. have proven that platelet micro-
vesicles (PMV) play multiple functions in metastasis.
For instance, PMV can increase tumour cells’ chemotaxis
to target organs through the transfer of the CD41 integrin
onto cancer cells (44). Zhu et al. observed a similar
phenomenon that human bone marrow mesenchymal
stem cell secretes exosomes upregulating VEGF and
CXCR4 expression on tumour cells through ERK1/2 and
p38 MAPK pathways (45).
In circulation, tumour cells lose the immunologic
suppressive protection of the microenvironment in the
primary tumour and become vulnerable to immune attack.
Besides the platelet armour, the CTC secretes a bulk of
exosomes modifying the immune system to escape im-
munologic surveillance. CTC inhibits the number and the
cytotoxic activity of NK cells through some exosome-
associated mechanisms such as inhibition of perforin
release, reducing CD3 and NKG2D (46) and inactivating
the Jak3 pathway (47). In addition, T cells are inhibited
through similar mechanisms like the apoptosis induced
by FasL and TRAIL-specific exosomes (48). Moreover,
with inhibiting anti-tumour effector lymphocytes, tumour
cells also activate the regulatory immune cells such as
Treg and myeloid-derived suppressor cells (MDSC). It has
been proven that exosomes in patient serum could trans-
form CD4CD25-T cells to CD4CD25Foxp3Treg
cells via TGF-D4 independent mechanisms (49). Further-
more, in breast cancer, melanoma and colonal cancer,
researchers observed that exosomes can influence the
maturation of DC skewing them to an immunologically
suppressive state like MDSC (50).
Extravasation
If the CTC survive, they will eventually reach a blood
vessel wall and a location of the metastatic site, which
mainly depends on the blood flow (the mechanical
hypothesis) and cell adhesion (the seed and soil hypoth-
esis). To colonize in the target organ, the tumour cell has
to extravasate from the capillary. This process includes
initially transient attachment, subsequent stable adhesion
and lastly transmigration.
As the mechanical hypothesis describes, extravasation
often occurs in small capillaries where the diameter is less
than that of CTC. As CTC encounters and rolls along
the vessel wall, there is a slipping motion between tumour
cell and endothelium, in a similar way to leucocyte,
which provides the possibility for receptorligand bond-
ing between tumour cell and EC (51). If ECs of specific
organs express sufficient adhesion molecules and provide
enough adhesive strength, the tumour cell will initiate a
transient weak adhesion. The selectin on EC, especially
E-selectin, mediates the homing of tumour cells (52). In
fact, the E-selectin in quiescent EC is at an extremely low
level, and it can be induced by inflammatory cytokines
such as TNF-a and IL-1 (53). It has been proven that
exosomes derived from tumour cells can stimulate immune
cells to release more inflammatory cytokines (33), and
exosomes themselves can act as a vector transferring
TNF-a (54). However, a detailed investigation into the
effect of cancer exosomes on E-selectin expression on
Taixue An et al.
4
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 27522 - http://dx.doi.org/10.3402/jev.v4.27522
EC has not yet been conducted, although E-selectin is an
important factor in cancer metastasis. In addition to the
E-selectin, Al-Nedawi et al. observed that the MAPK
pathway will be activated when EC takes up EGFR-
containing exosomes derived from cancer cells (55). It has
been proven that in inflammatory disease, MAPK acti-
vation can facilitate cell extravasate from the vessel (56).
Research into the effect of cancer exosomes on selectin
expression of EC is quite sparse for the moment.
Shortly, after the initial rolling stage, there is a stable,
firm attachment between elongated tumour cells and
activated EC. This is mainly mediated by the interaction
of tumour cell integrins and immunoglobulin superfamily
members like ICAM-1, and VCAM-1 (57). It seems that
the integrinb1 is constantly activated without stimuli
(58) and, by contrast, the increase of integrin ligand on
activated EC controls this stable adhesion. Taverna et al.
found in chronic myelogenous leukaemia that, at the
beginning of stable adhesion, the tumour exosome could
induce VCAM-1 and ICAM-1 expression in EC (36);
after a long period of arrest, tumour exosomes will then
downregulate VCAM-1-promoting tumour cells to seek a
site with more chemoattractants.
During the adhesion stage, tumour cell driven by
chemoattractants crawls along the blood vessel wall to
a preferred place of transmigration where the level of
adhesive molecules and its ligands is high enough to
initiate the transmigration. In this process, the tumour cell
turns from round to elongate and, further, extends the
protrusions into the gap resulting in the opening of the
junction and eventual transmigration. Since the tumour
cell is twice as big as the leucocyte, it cannot transmigrate
in the same way as the leucocyte without impairing the
endothelium (51). Specifically, the tumour cell disrupts
the adhesion junction and induces EC retraction, even
apoptosis (59), which thus shares many similarities with
intravasation. The only clue about exosomes causing EC
apoptosis comes from the research on platelet-derived
exosomes in sepsis (60), and the act of tumour exosome
on EC apoptosis in extravasation needs more researches.
The above-mentioned process mainly refers to paracellu-
lar transmigration which involves the tumour cell squeez-
ing between adjacent ECs. Transcellular transmigration
which allows tumour cell transmigration through the EC
directly still remains an enigma (61).
Proliferation
After extravasation, the disseminated tumour cells may
die, or enter a state of dormancy of proliferation, which
is determined by the tumour cells and the microenviron-
ment at the secondary site, namely the niche (62). As
the primary site, the niche is a crucial part of tumour
progression in the metastatic organ. Their functions include
facilitating CTCs homing, promoting the extravasation,
fostering an inflammatory milieu as the primary tumour,
deregulating the immune system, providing survival and
proliferative signals, keeping ‘‘stemness’’ properties of
cancer stem cells and maintaining dormancy. It has
been determined that, in fact, the pre-metastatic niche
has been changed by factors secreted by primary tumours
prior to the arrival of CTCs (63).
Castellana et al. show that exosomes have the same
systemic effects on the remodelling of the pre-metastatic
niche as the soluble factors in primary tumours (64). It
seems that exosome is an essential companion for soluble
factors’ initiating pre-metastatic niche (65,66). Exosomes
derived from tumour cells can transform the host cell to a
pre-metastatic phenotype favouring tumour cell survival
and proliferation. For instance, exosomes can change
genes expression associated with the formation of the pre-
metastatic niche in the lymph node stroma cells and
lung fibroblasts in metastatic rat adenocarcinoma (67).
In addition to directly changing the stroma cells, exo-
somes can educate and recruit bone marrow derived cells
(BMDCs), which are an important constituent in the pre-
metastatic niche. Peinado et al. observed this and further
showed that BMDC mobilization is caused by horizontal
transfer of the MET oncoprotein by exosomes (68).
If the niche is not suitable, tumour cells will enter
dormancy waiting for an appropriate condition. This
dormancy can be considered as a protective mechanism
of cancer cells. Exosomes derived from bone marrow
mesenchymal stem cells can transfer miR-23b and down-
regulate MARCKS gene expression promoting the dor-
mancy (69). It is highly possible that exosomes regulate
cancer cell’s dormancy, although the dormancy is not yet
fully understood. A biomarker indicating the dormancy is
of great meaning for recurrence and drug resistance.
Others
Four characteristic features in tumour progression
and metastasis, inflammation, immunity, hypoxia and
angiogenesis, are highly interrelated and together influence
the development of tumour. They accompany tumour
cell development and are not limited to a certain step of
metastasis. The influences on metastasis mediated by
exosomes are thus demonstrated separately in the follow-
ing section.
It has long been recognized that there is an inextricable
connection between chronic inflammation and tumour
development. It promotes tumour development by diverse
pro-inflammatory factors, which could perturb cell sig-
nalling pathways and increase the expression of growth-
promoting genes, such as cytokines and interleukins.
As a container of various pro-inflammatory factors, exo-
some is an important part of inflammation associated
with metastasis (70). Fabbri et al. show that miR-21 and
miR-29a in tumour-derived exosome can reach, bind to
and activate the Toll-like receptor (TLR) such as murine
TLR7 and human TLR8 in the intracellular endosomes
The potential of exosome as personalized diagnostic marker
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of immune cells. The activated TLRs can trigger a pro-
metastatic inflammatory response via NF-kB signalling
pathway, and ultimately lead to tumour growth and
metastasis (71).
Local cancer-associated inflammation can also induce
a severe immunosuppression. Aberrant nucleic acids and
other products in tumours can recruit and activate im-
mune cells related to inflammation. This immune response
elicited by the tumour is generally unable to eradicate
the tumour, and, on the contrary, it will remodel the micro-
environment in the primary site and select the genetically
fittest cancer cells that could evolve into aggressive malig-
nant tumours. The tumour-specific antigens harboured in
tumour-derived exosomes can initiate tumour immunity
and participate in tumour-associated immunity. Clayton
et al. reported that the NKG2D ligands in tumour-derived
exosome can inhibit the cytotoxic CD8T cells and
nature killer cells inducing an immunosuppression (72).
Compared with directly influencing cytotoxic T cell,
exosome can also impact the immune system via regula-
tory cells. For example, TGF-b1 present at the exosome
surface can increase the activity and number of Foxp-3
positive Treg, which inhibit the proliferation response
of CD8 T cells to interleukin-2 (73). In addition, the
antigen in tumour exosomes can modulate dendritic cells
towards a more suppressive cell phenotype in favour of
the escape of tumour cells (74).
Since the high proliferation rate of tumour cells
surpasses that of vasculature expansion, the majority of
the tumour is hypoxia. Furthermore, the new blood vessels
in the tumours are abnormal, leaky or non-functional.
For the increasing genomic instability induced by hyp-
oxia, cancer cells mutate and adapt to the tumour
microenvironment rapidly. Consequently, cancer cells
with low apoptotic potential and high aggressive property
are screened out by the hypoxia (75). Additionally, much
necrotic debris derived from hypoxia comprises pro-
inflammatory factors, which can recruit a host of inflam-
matory cells (76). For example, King et al. showed that
hypoxia-mediated activation of HIF-1a enhances the
release of tumour-derived exosomes, which promotes
cancer cell survival and invasion in a breast model (77).
When a solid tumour grows beyond 12 mm in
diameter, it has to develop its own blood vessel networks
to supply nutrients and carry away wastes (78). Angio-
genesis not only allows further growth of the tumour
but also provides an avenue for metastatic tumour cells
to intravasate into the circulation and establish distant
metastases (79). It is increasingly clear that cancer-derived
EV exerts complex effects on angiogenesis-associated cells
contributing to vessel formation through delivery of angio-
genic proteins and nuclear material (80). For example,
Hood et al. showed that exosomes derived from melanoma
can promote endothelial spheroid formation in a dose-
dependent manner (81). Nazarenko et al. reported that
tumour-derived tetraspanin Tspan8 positive exosomes
can efficiently induce angiogenesis in tumours by increas-
ing levels of von Willebrand factor, VEGF, VEGF-
R2 and other factors, which could drive EC proliferation,
migration and sprouting (82).
Exosome as a biomarker in personalized
diagnostics
The potential of the exosome as a biomarker
As a complicated disease with numerous genetic abnorm-
alities, a prominent feature of cancer is its high hetero-
geneity which exists not only amongst different lesions
in 1 patient, but also cells in the same tumour mass. It is
not unusual that patients with an identical type of cancer
and stage have variations in genotype and/or phenotype.
This fingerprint-like variability results in patients’ differ-
ent responses to antitumor therapies, for example, some
active drugs have no effects on certain patients, or even
have adverse effects. The practice of ‘‘one medicine for
all patients with the same diseases’’ cannot stand any
more. Since Kewal K. Jain first put forward the concept
of personalized medicine in 1998, it has revolutionized
our approach to the cancer therapy (83). Personalized
medicine suggests that the tumour therapy should be
tailored according to individual characteristics and re-
sponses to the specific treatment. In personalized medi-
cine, the customized treatment depends on information
about the molecular characteristics of the cancer signa-
ture, namely the personalized diagnostics. Biomarkers
in personalized diagnostics can be divided into several
subgroups according to their application: screening, early
diagnosis, prognosis, prediction, monitoring and compa-
nion diagnostics. Prognostic markers aim to predict
the likely outcome of cancer patients overall, while the
predictive markers predict the likelihood of a response
to certain therapies, both of which often cannot be
distinguished, especially in recurrence. Companion diag-
nostics, firstly approved by the FDA in 2013, come along
with the development of personalized medicine, which
identifies potential patients responding to a particular
therapy.
Although traditional biomarkers have been widely
and maturely utilized in personalized medicine, their
inherent limitations cannot be neglected. First, the most
common method to detect pharmacogenomically rele-
vant sequences is fluorescence in situ hybridization,
which depends on the sample from biopsy. As Gerlinger
pointed out, about two-thirds of mutations in a single
biopsy cannot be detected uniformly throughout the
whole sampled region of the same tumour (84). Thus,
a single biopsy is incapable of representing the landscape
of genomic abnormalities in 1 tumour, which impede
doctors’ understanding the global situation. Secondly,
tissue biopsy, the best method of diagnosis, is invasive
Taixue An et al.
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and dangerous, and is unable to be applied to repeated
diagnosis. Thirdly, the low specificity of serum biomarkers
in present clinical diagnosis may contribute to a low
efficiency of diagnosis.
As mentioned above (illustrated by Table I and Fig. 1),
exosomes act as communicative vectors between tumour
cells and the carcinogenesis and metastasis microenviron-
ment. They possess great potential as cancer biomarkers
in personalized medicine. Firstly, the bioactive molecules
transferred by exosomes have high specificity, which
can represent the identity and state of their parental
cells. Besides, exosomes bear multifunction in tumour
development, such as promoting carcinogenesis, trans-
forming cancer cells’ phenotype and modifying the cancer
microenvironment. Additionally, these exosomes repre-
sent sensitive and rapid responder towards environmental
stimuli. The amount and composition of molecules in exo-
somes are associated with tumorigenesis, tumour progres-
sion and alleviation, for example, the number of exosomes
increasing with aggravation in gastric cancer (13,14).
Compared with traditional biomarkers, exosomes
bear some other advantages potentially. Firstly, exosomes
can travel across the endothelium into the circulation
allowing serum detection. In contrast to invasive tissue
biopsy, exosomes are effective biomarkers in the diversi-
fied diagnosis of personalized medicine. Secondly, exo-
somes are akin to vessels enriched with much information
about the parental cells, and the cargoes in exosomes
are protected by the phospholipid bilayer from degrada-
tion by proteinases and nucleases. Consequently, biomar-
kers at a relatively low expression are much easier to be
detected through isolating exosomes. For instance, some
biomarkers such as PCA3 and TMPRSS2 are mRNAs
not easily detected in body fluids, but appear in exosomes
in prostate cancer (86). Thirdly, analysing the fraction of
exosomes can effectively weaken the serum matrix effect
and reduce the dynamic range. Fourthly, exosomes are
constituently secreted by various cells and the number
of exosomes increases obviously in the serum of cancer
patients (87). Accordingly, it is reasonable to assume that
the representativeness of exosomes is better than fine
needle biopsy (12), which is of great meaning for the
accuracy of personalized diagnostics.
By now, a huge amount of effort has been devoted to
the utilization of exosome as a cancer biomarker. Some
promising biomarkers that are found in clinical studies
with patients’ body fluid are summarized in Table II.
Although the sample size and standard operating proce-
dures need optimization, these studies throw light upon
some important potential biomarkers. As novel biomar-
kers, some clinical validated traditional molecules are also
found in exosome-like prostate-specific antigen (PSA).
These traditional molecules in exosomes possess higher
specificity and relevance to disease than their total amount
in serum or plasma (88,89). It seems the combination of
traditional and novel biomarkers may achieve the highest
prediction value (132). Additionally, the biomarkers in exo-
some of ovarian cancer (12), melanoma (68) and pancreatic
adenocarcinoma (90) may be used in cancer stratification as
they change regularly in antitumor therapy. Exosomes may
be exploited as a companion diagnostic to identify the
susceptible population and eligible patients for drugs. In the
research of Kahlert et al. the mutated KRAS in exosome is
associated with poor therapeutic response and has the
great possibility to be utilized as a companion diagnostic
for Erbitux (91,92). In Thakur’s research, the mutated
BRAFV600E in exosome can be considered as a compa-
nion diagnostic biomarker for Vemurafenib, a melanoma
drug (133).
The technologies in exosome diagnosis
At present, the isolation of exosomes mainly depends on
non-specific physicochemical properties such as particle
size, density and solubility, all of which cannot separate
exosome from EVs thoroughly. Differential centrifu-
gation, as the earliest and most classical method, is
widely used in the exosome research. However, differential
centrifugation is unable to separate exosomes from other
EVs based on density. It is difficult to avoid aggregations
of exosomes, contamination from co-precipitated lipo-
protein and protein complexes and the shear forces on
exosomes. It is also an operator-dependent, low-throughput
and low yield method. Because of these flaws, centrifuga-
tion is unsuitable for routine clinical practice. In recent
years, researchers have developed various methods to
overcome these shortcomings, such as exosome precipita-
tion, magnetic beads and size-exclusion chromatography.
Their advantages and limitations are listed in Table III,
which in summary indicate that exosomes isolated by
commercialized exosome precipitation reagent have a
greater purity and quantity than the other 3 methods
(134136). However, it remains far from satisfactory due
to low purity, which impairs downstream analysis. As
high quality exosomes are critical for downstream ana-
lyses, there is an urgent need for a standard, efficient
and reliable method for both exosome basic research and
in clinical practice.
During the last 2 decades, nucleic acid testing technol-
ogies have progressed tremendously allowing us to detect
exosomal nucleic acid derived from diverse body fluids.
Several platforms have been applied to exosome RNA
analysis, such as microassay, digital polymerase chain
reaction (PCR) and next-generation sequencing, and
each has its own advantages. The digital PCR provides
a higher sensitivity and precision with similar methodol-
ogy to quantitative PCR. Chen et al. were able to reliably
detect the mRNA mutations in isocitrate dehydrogenase
(IDH1) derived from exosomes in patients’ CSF and
which has a high concordance with biopsy (137). Next-
generation sequencing can provide thousands of gene
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Table I. The contribution of EV to key steps in tumour metastasis
Stage Phenotype Donor cell Associated molecule Target References
Invasion Induce EMT Normal prostate stromal cells
overexpressing miR-409
miR-409 Prostate cancer cells (23)
Reduce the intercellular adhesion Prostate cancer E-cadherin and b-catenin Prostate cancer PC3 cells (25)
Degrade extracellular matrix Four human tumour cell lines MMP-9, MMP-2 and uPA extracellular matrix (85)
Promote migration Adipose mesenchymal stem cell Wnt/b-catenin pathway Breast cancer cell line
MCF-7
(26)
Promote cell protrusion and invasive migration Fibroblast Wnt/PCP activated by CD81 Breast cancer cell (27)
Promote adhesion of tumour cell to ECM Prostate cancer ITGA3 and ITGB1 Tumour cell (28)
Intravasation Activate immune cells to increase blood
permeability
Various body fluids of ovarian cancer
patients
TLR-dependent signalling pathways THP-1 cells (33)
VE-cadherin endocytosis and increased
vascular permeability
Human ovarian carcinoma cell lines
CABA I and A2780
VEGF EC (35)
Induce the EC retraction Chronic myelogenous leukaemia
(CML) cells
IL-8 EC (36)
Induce cancer cell intravasation Laryngocarcinoma, hepatocellular
carcinoma and breast cancer
Pdcd4 regulated by miR-21 Tumour cell (38)
Decreases the tight junction of endothelium Metastatic breast cancer cell Tight junction protein ZO-1 EC (42)
Circulation Increase the chemotaxis of tumour cell Platelets activated by tumour cell CD41 integrin Five human lung cancer
cell lines
(44)
Chemotaxis distribution Mesenchymal stem cells CXCR4 Human gastric carcinoma (45)
Inhibit NK cell Sera of patients with AML CD3, NKG2D and Jak3 pathway NK cell (47)
Inhibit T cell Breast cancer cell line HCC1806 FasL and TRAIL T cell (48)
Induce Treg cell Serum of ovarian cancer patients TGF-b and IL-10 CD4 CD25-T cell (49)
Extravasation Activate EC Melanoma TNF-a Neighbouring cells (54)
Change EC to favour the extravasation Human squamous cell line EGFR EC (55)
Induce VCAM-1 and ICAM-1 expression in EC Chronic myelogenous leukaemia
(CML) cells
VCAM-1 and ICAM-1 EC (36)
Proliferation Transform the host cell to a pre-metastatic
phenotype
Prostate carcinoma cell lines Extracellular signal-regulated kinase 1/2
phosphorylation and MMP-9 up-regulation
Fibroblasts (64)
Alter gene expression associated with pre-
metastatic niche
Metastatic rat adenocarcinoma
BSp73ASML
miRNAs such as miR-494 and miR-542-3p Lymph node stromal cells
and lung fibroblasts
(67)
Recruit the BMDCs and induced vascular
leakiness at pre-metastatic sites
Melanoma Receptor tyrosine kinase MET Bone marrow progenitors (68)
Promote dormancy Bone marrow mesenchymal stem
cell
miR-23b and MARCKS gene Human breast cancer cell (69)
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Table II. Molecules in EV from body fluids of patients with cancer as potential markers for personalized medicine
Caner type Material Body fluids Biomarkers Potential application References
Prostate cancer Protein Plasma, serum Survivin Monitoring (93)
Protein Plasma PSA Diagnosis/prognosis (88)
Protein Urine PSA Diagnosis/monitoring (89)
Protein Urine b-catenin Screening (94)
Protein Urine PCA-3, TMPRSS2:ERG Diagnosis/monitoring (86)
miRNA Plasma, serum and urine miR-107, miR-141, miR-375, miR-574-3p Diagnosis/prognosis (95)
miRNA Serum miR-141 Diagnosis/prognosis (96)
miRNA Serum 15 miRNAs Diagnosis/monitoring (97)
Vesicle Serum Platelet microparticle number Prognosis (98)
Vesicle Plasma Microvesicle number Diagnosis/prognosis (99)
Ovarian cancer Protein Plasma Claudin-4 Screening (100)
Protein Plasma TGF-beta1, MAGE3/6 Prediction/monitoring (12)
Protein Serum L1CAM, CD24, ADAM10, EMMPRIN Diagnosis/prognosis (101)
Protein Serum IgG recognized exosome antigen Diagnosis
Protein Ascites CD24, EpCAM Diagnosis (102)
Protein Ascites MMP2, MMP9, uPA Diagnosis (103)
miRNA Serum 12 miRNAs Screening (104)
Vesicle Serum EpCAM()exosome number Screening (104)
Lung cancer Protein Serum EGRF Prognosis (91)
Protein Urine LRG1 Diagnosis (105)
Protein Pleural effusion SNX25, BTG1, PEDF, thrombospondin Diagnosis (106)
miRNA Serum miR-486, miR-30d, miR-1, miR-499 Diagnosis/prognosis (107)
miRNA Plasma 6 miRNAs Diagnosis (108)
miRNA Plasma let-7f, miR-30e-3p, miR-223, miR-301 Diagnosis (109)
miRNA Plasma miR-205, miR-19a, miR-19b,
miR-30b, miR-20a
Monitoring (130)
miRNA Plasma 10 miRNAs Screening (108)
miRNA Plasma 12 miRNAs Screening/prognosis (110)
Vesicle Plasma EpCAM()exosome number Screening/prognosis (110)
Vesicle Plasma Microvesicle number Prognosis (131)
Glioblastoma Protein Plasma EGFR, EGFRvIII, PDPN, IDH1R132H Monitoring (111)
Protein Serum EGFRvIII Prognosis (112)
miRNA Serum miR-21 Diagnosis/prognosis (113)
miRNA Serum RNU6-1, miR-320, miR-574-3p Diagnosis (114)
miRNA Cerebrospinal fluid miR-21 Diagnosis (115)
Breast cancer miRNA Blood, milk, ductal fluids miR-16, miR-1246, miR-451, miR-720 Prognosis (116)
miRNA Serum miR-200a, miR-200c, miR-205 Diagnosis (117)
Protein CD24, EpCAM (117)
Protein Serum HER-2 Monitoring (118)
miRNA Serum miR-21 Prognosis (41)
Pancreatic cancer miRNA Serum miR-17-5p, miR-21 Diagnosis (90)
DNA Serum KRAS Companion
diagnosis/prognosis
(92)
Protein Plasma EGFR Diagnosis (119)
mRNA Saliva Apbb1ip, ASPN, Daf2, FoxP1,
Bco31781, Gng2
Diagnosis (120)
Colorectal cancer Protein Ascites Claudin-3 Diagnosis (121)
miRNA Serum 7 miRNAs Diagnosis (122)
Vesicle Plasma Microvesicle number Diagnosis/prognosis (123)
Melanoma Protein Plasma Caveolin-1 Diagnosis/prognosis (124)
Protein Plasma TYRP2, VLA-4, HSP70, HSP90‘ Prognosis (68)
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sequences at a time, presenting the diseases relevant gene
mutations and aberrant miRNA expression. Jenjaroenpun
et al. obtained a different transcriptome in exosomes
derived from highly and low malignant breast cancer by
next-generation sequencing (138). Like the detection of
other material, the consistency and the transformation
between data from different technologies are perturbing
problems, which need further investigation.
In the detection of exosome proteins, great efforts are
being devoted to specific antibody based technologies,
which may directly analyse biomarkers in a cluster of
exosomes from body fluids without isolation. These tech-
nologies mainly consist of ELISA, flow cytometry (139),
protein microarray (140), handheld diagnostic magnetic
resonance (141), nanoplasmonic exosome technology (142)
and Exoscreen (143). In converse, mass spectrometry
has been also utilized to analyse proteins in exosomes.
Although mass spectrometry can provide an accurate
concentration of proteins in exosomes (144), its applica-
tion to clinical practice is obviously in the primary stage.
Challenges that these technologies have to face include
low sample throughput, the variability and complexity
of body fluids and complicated sample preparation.
Challenges and perspectives
Although the studies of vesicles has been performed
for decades since the first observation in 1946 (145),
the utilization of exosomes in diagnosis is a relatively
new field. There remain lots of challenges to overcome in
exosome diagnostics. Isolation of exosomes, undoubtedly,
is the biggest problem, including not only standardizing the
protocol in research but also creating an efficient, stable
and clinically feasible extraction method. Additionally,
the huge amounts of data from the developing detection
technologies provide a chance not only to find the key
molecules but also to render a problem of ascertaining the
valuable marker amongst numerous molecules. Moreover,
present potential biomarkers, the majority of which are
derived from small-sample studies, need large multicentre
validation. The accurate correlation between these poten-
tial markers and clinical practice also requires deeper and
more rigorous studies. Last but not the least, the knowl-
edge of the basic properties of exosomes is insufficient
ranging from the factors affecting exosome synthesis,
secretion and transfer to storage conditions of exosomes,
which is crucial to the accuracy of exosome diagnosis.
As a carrier encapsulating a variety of molecular
information, the potential and feasibility of exosome
Caner type Material Body fluids Biomarkers Potential application References
Gastric cancer Protein Serum CCR6, HER-2/neu, EMMPRIN,
MAGE-1, C-MET
Diagnosis/prognosis (14)
Vesicle Plasma Platelet microparticle number Diagnosis (13)
Bladder cancer Protein Serum EPS812, mucin-4 Diagnosis (125)
Mucinous
adenocarcinoma
Protein Plasma Tissue factor, MUC1 Monitoring (126)
Oesophageal
squamous cell
carcinoma
miRNA Serum miR-21 Prognosis (127)
Cervical cancer miRNA Cervicovaginal lavage miR-21, miR-146a Diagnosis (100)
Acute leukaemia miRNA Plasma miR-92 Diagnosis (128)
Hepatocellular
carcinoma
Vesicle Serum Microvesicle number Diagnosis (129)
Table III. Isolation strategy of EV
Principle Methods Advantages Limitations
Buoyancy Successive differential
centrifugation
High purity and widely utilized Highly labour intensive, time consuming, low
yield and limited processing capacity
Particle size Microfiltration, ultrafiltration and
size-exclusion chromatography
Easy manipulation and relatively
high yield
Susceptible to the contamination of protein
complexes
Affinity Immunomagnetic sorting,
microfluidic device and exoscreen
High specificity, high purity, low
cost and convenient
Low yield, cannot capture all kinds of exosome
and there is no molecule specific to exosome
Precipitation Some commercialized reagents Convenience, high yield, do not
need much starting material
Expensive and susceptible to the contamination
of precipitated molecules
Table II (Continued)
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diagnosis is supported by an increasing number of
publications. Many markers in cancer exosomes are asso-
ciated with the state of tumours. To exploit exosomes as
a biomarker, it is essential to determine the applied range
of novel biomarkers and illustrate their relations with
clinical validated markers. Besides, a reference standard
for exosome molecule profile is needed, like the referenced
genomic DNA used in present personalized medicine.
For instance, Huang et al. have applied next-generation
sequencing to characterize the profiles of exosome RNA
in 3 healthy human plasma samples (146). Furthermore,
researchers have assumed that surface markers will dis-
tinguish tumour-derived exosomes from host exosomes.
Unfortunately, many surface markers are shared by exo-
somes derived from various cancer cell lines and between
tumour and non-tumour tissues. Exosome membrane
proteins are of significant meaning to exosome capture.
It provides a chance to improve the specificity of exosome
diagnosis. The Exosome protein database such as Exo-
Carta constructed by ISEV, as a powerful instrument,
will assist researchers to explore the synthesis mechanism
and function of content in exosome (144) as well as Vesicle
pedia (147).
Conclusion
With the development of recent research, exosomes are
no longer recognized as merely part of a physiological
process to remove unwanted cellular debris, but an im-
portant tool of intercellular communication, which can
transport bioactive molecules and influence recipient cells.
In tumour progression, exosomes are secreted by cancer
cells to modify the tumour itself and its microenvironment
and to participate in every step of metastasis. Since the
profile of exosome contents is origin specific and because
of the many other advantages, exosomes are promising
cancer biomarkers in personalized medicine. Although
the isolation of exosomes is a troubling issue, exosomes
have the potential to be a kind of liquid biopsy with a
higher sensitivity and accuracy.
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